SIGY Archives - Page 2 of 2

Executive Moves

Sigyn appoints internationally recognized nephrologist Dr. Alexander Yevzlin to SAB

Sigyn Therapeutics (OTC:SIGY) appointed Alexander Yevzlin, M.D., currently prof. of medicine and director of interventional nephrology at the University of Michigan, to its scientific advisory board. Dr...

March 9, 2022

Executive Moves

Sigyn Therapeutics names accomplished financial executive Jeremy Ferrell as CFO

Sigyn Therapeutics (OTC:SIGY) appointed Jeremy Ferrell as CFO, effective March 9, 2022, with overall responsibility for operational finance, budgeting, and financial reporting, as well as helping manage Sigyn’s...

March 2, 2022

Developments

Sigyn Therapeutics completes animal studies; Sigyn Therapy safe and well tolerated

Sigyn Therapeutics (OTC:SIGY) reported successful completion of an in vivo study that demonstrated Sigyn Therapy, its novel blood purification technology, to be safe and well tolerated. Data resulting from...

February 23, 2022

Feature

Sigyn Therapeutics hopes to file IDE in Q2 for human studies of Sigyn Therapy

Sigyn Therapeutics (OTC:SIGY) hopes to file in the second quarter this year an investigational device exemption (IDE) with the FDA to initiate human clinical studies of its Sigyn Therapy, a dual-function blood...

February 15, 2022

Developments

Sigyn Therapeutics featured in BioSpace, twice

BioSpace, a leading life sciences publication, featured Sigyn Therapeutics (OTC:SIGY) and its novel extracorporeal blood purification technology twice in January. One article profiled the company and its Sigyn...

January 19, 2022

Developments

Sigyn outlines 2021 achievements; 2022 clinical, corporate outlook

In a letter to shareholders, chairman and CEO, Jim Joyce of Sigyn Therapeutics (OTC:SIGY), said that in the face of a pandemic that paused and shuttered numerous clinical research programs, “we translated our vision for...

January 4, 2022

Developments

Sigyn Therapeutics successfully completes study for gram-positive bacterial toxins

Sigyn Therapeutics (OTC: SIGY) reported that preclinical in vitro studies have validated the ability of Sigyn Therapy to deplete the presence of gram-positive bacterial toxins from human blood plasma. Sigyn...

December 1, 2021

Developments

Sigyn Therapeutics featured on NPR’s Tech Nation

Jim Joyce, CEO of Sigyn Therapeutics (OTC Markets:SIGY) was interviewed by National Public Radio’s Tech Nation about the treatment of life-threatening inflammatory conditions precipitated by cytokine storm syndrome. In...

August 30, 2021

Feature

Taming cytokine storm syndrome with Jim Joyce of Sigyn Therapeutics

As a co-founder, chairman and CEO of Sigyn Therapeutics (pronounced Sig-en) (OTCMarkets:SIGY), a medical device company developing a blood purification system to treat life-threatening inflammatory conditions, including...

August 10, 2021

Tag - SIGY

Sigyn appoints internationally recognized nephrologist Dr. Alexander Yevzlin to SAB

Sigyn Therapeutics names accomplished financial executive Jeremy Ferrell as CFO

Sigyn Therapeutics completes animal studies; Sigyn Therapy safe and well tolerated

Sigyn Therapeutics hopes to file IDE in Q2 for human studies of Sigyn Therapy

Sigyn Therapeutics featured in BioSpace, twice

Sigyn outlines 2021 achievements; 2022 clinical, corporate outlook

Sigyn Therapeutics successfully completes study for gram-positive bacterial toxins

Sigyn Therapeutics featured on NPR’s Tech Nation

Taming cytokine storm syndrome with Jim Joyce of Sigyn Therapeutics

General

More